Cancer Vaccine Tumor Rechallenge Study Services

What a Tumor rechallenge Study Is and Why It Matters

A tumor rechallenge study is a preclinical in vivo assessment in which animals that have been vaccinated and subsequently challenged with tumor cells are later re-exposed to the same tumor line. The readout helps sponsors investigate whether a vaccine candidate is associated with tumor control and with resistance to re-growth on second exposure, which is commonly interpreted as evidence consistent with immunological memory. For cancer vaccine programs, rechallenge data are typically requested alongside primary tumor-growth-inhibition data to support go/no-go decisions.

Parallel antigen-specific T cell response assays can characterize immune responses associated with protection in the selected model.

What the Service Covers

Model and Study Design Scoping

We work with you to select a syngeneic tumor model and define vaccination schedule, challenge and rechallenge timing, group sizes.

Vaccination, Challenge, and Rechallenge Execution

Studies are run in vivo according to the agreed plan, including immunization, primary tumor challenge, tumor growth monitoring, and rechallenge of eligible animals. Handling and welfare practices follow the approved animal protocol.

Tumor Growth and Survival Readouts

Primary readouts include tumor growth curves, individual tumor measurements, and survival monitoring through the observation window. Additional readouts such as body weight are recorded when included in the scope.

Optional Immunological Support Assays

When project-scoped, supporting readouts such as ex vivo immune cell profiling or antigen-specific response assessment can be incorporated to add context to rechallenge observations. These are defined during design and are not part of every study by default.

How a Rechallenge Study Engagement Works

Consultation and Feasibility Review We review your candidate, prior data, and study objectives, then confirm whether a rechallenge design is appropriate for your program and what model options fit the question.

Study Plan and Scope Agreement Model, group structure, vaccination and challenge schedule, monitoring frequency, endpoints, and deliverables are defined in a written study plan. Scope changes are handled through an agreed amendment.

In-Life Execution and Monitoring Vaccination, primary challenge, tumor measurement, and rechallenge are carried out per the approved plan, with scheduled monitoring and documentation of in-life observations.

Data Review and Reporting Tumor growth and survival data are compiled, checked against the study plan, and summarized in a report. Optional supporting assays are reported separately when they are included in the agreed scope.

Typical Deliverables for Tumor rechallenge Studies

Deliverable	What It Covers
Study design summary	A written protocol outline covering tumor model selection, vaccination schedule, rechallenge timing, group allocation, and the endpoints to be recorded, agreed before study start.
In-life records	Cage-side observations, body weight and clinical scoring records, and vaccination and rechallenge administration logs are maintained and provided with the study report.
Tumor growth data	Individual and group-mean tumor volume measurements from the primary implantation phase and the rechallenge phase, presented as tabulated data and growth curves.
Rechallenge outcome summary	A summary of tumor take, growth, or rejection in rechallenged animals relative to the agreed control groups, with the raw supporting data included.
Immune readout data, when scoped	Results from any additional sample analyses agreed at design, such as flow-based immune cell profiling or ex vivo assays, reported with the methods used.

Why Sponsors Scope Rechallenge Studies With Us

Rechallenge-specific design discipline

Rechallenge studies depend on clean separation between the primary vaccination phase and the later tumor challenge. We plan group allocation, challenge timing, and control arms around that structure so the rechallenge readout can be interpreted against the agreed comparators.

Controls built into the plan

Interpretable rechallenge data needs the right comparators. Naive and vehicle or adjuvant-only groups, plus non-rechallenged reference animals where scoped, are defined during study design rather than added after data review.

Flexible model and readout scope

Tumor model, vaccine format, dosing schedule, rechallenge interval, and the depth of immune readouts are set case by case in the project scope. Additional analyses can be incorporated when agreed at design, so the study matches the question being asked.

Research reference

1. Spatiotemporally engineered tumor-derived extracellular vesicle-based scaffold vaccine for personalized cancer immunotherapy

Nature Communications. 2026. DOI: 10.1038/s41467-026-70924-z.

View article

Plan a Tumor rechallenge Study for Your Cancer vaccine Program

Share your vaccine construct, tumor model preference, and the endpoints your program needs. Our team will outline a rechallenge design with scoped groups, dosing, monitoring, and readouts, then confirm deliverables and timelines in a written study plan before work begins.

The study scope can include antigen-specific T cell response assays at selected time points to complement tumor-outcome measurements.

Request a Study Consultation